Long Georgina V, Dummer Reinhard, Schadendorf Dirk, Santinami Mario, Atkinson Victoria, Mandalà Mario, Chiarion-Sileni Vanna, Larkin James, Nyakas Marta, Dutriaux Caroline, Haydon Andrew, Robert Caroline, Mortier Laurent, Schachter Jacob, Lesimple Thierry, Plummer Ruth, Dasgupta Kohinoor, Haas Tomas, Shilkrut Mark, Gasal Eduard, Kefford Richard, Kirkwood John M, Hauschild Axel
Georgina V. Long, MD, PhD, Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Reinhard Dummer, MD, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland; Dirk Schadendorf, MD, PhD, University Hospital Essen, Essen, Germany, and German Cancer Consortium, Heidelberg, Germany; Mario Santinami, MD, Fondazione Istituto Nazionale Tumori, Milan, Italy; Victoria Atkinson, MD, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, and University of Queensland, Brisbane, QLD, Australia; Mario Mandalà, MD, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy; Vanna Chiarion-Sileni, MD, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy; James Larkin, MD, PhD, Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Marta Nyakas, MD, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, MD, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France; Andrew Haydon, MD, PhD, The Alfred Hospital, Melbourne, VIC, Australia; Caroline Robert, MD, PhD, Institute Gustave Roussy, Paris, France; Laurent Mortier, MD, PhD, Université de Lille, Institut National de la Santé et de la Recherche Médicale U 1189, Centre Hospitalier Universitaire Lille, Lille, France; Jacob Schachter, MD, PhD, Sheba Medical Center, Tel HaShomer, Israel, and Tel Aviv University, Tel Aviv, Israel; Thierry Lesimple, MD, MSc, Centre Eugène Marquis, Rennes, France; Ruth Plummer, MD, PhD, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Kohinoor Dasgupta, PhD, Novartis Healthcare, Hyderabad, India; Tomas Haas, PhD, Novartis AG, Basel, Switzerland; Mark Shilkrut, MD, PhD and Eduard Gasal, MD, Novartis Pharmaceuticals, East Hanover, NJ; Richard Kefford, MD, PhD, Melanoma Institute Australia, The University of Sydney, Macquarie University, and Westmead Hospital, Sydney, NSW, Australia; John M. Kirkwood, MD, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; and Axel Hauschild, MD, University Hospital Schleswig-Holstein, Kiel, Germany.
J Clin Oncol. 2019 May 20;37(15):1356-1358. doi: 10.1200/JCO.19.00004. Epub 2019 Apr 2.
